Cerevel Therapeutics Holdings Inc Aktie News

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders. Halper Sadeh encourages Cerevel shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (21...

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is s...

Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to be on a buying spree AbbVie is willing to spend about $8.

AbbVie Inc announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or a total equity value of approximately $8.7 billion.  Cerevel's portfolio includes drugs such as Emraclidine, an experimental treatment for both schizophrenia and Alzheimer's disease psychosis, which is currently in a Phase I study in elderly healthy volunteers.